Akinion Pharmaceuticals AB

Akinion Pharmaceuticals AB is rated 3 out of 5 in the category pharmaceuticals. Read and write reviews about Akinion Pharmaceuticals AB. Founded in 2009, Akinion Pharmaceuticals AB is a privately owned Swedish biotech company with a UK subsidiary focused on the discovery and development of signal transduction inhibitors for the treatment of acute myeloid leukemia (AML). Our vision is to make a significant contribution to the quality of life and survival rates of AML patients. KDev Investments AB, the majority shareholder in Akinion Pharmaceuticals, is a vehicle jointly owned by Karolinska Development and Rosetta Capital IV Sarl (a Luxembourg fund-management vehicle under the framework of Rosetta Capital Ltd). For more information, please visit http://www.akinion.com/